References
- KDOQI: National Kidney Foundation III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis 2006;47(Suppl 3):S86-S108.
- Nissenson AR. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989;9 (1 Suppl 2):25-31.
- Kausz AT, Obrador GT, Pereira BJ. Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 2000;36(Suppl 3):S39-51. https://doi.org/10.1053/ajkd.2000.19930
- Rigden SP, Montini G, Morris M, Clark KG, Haycock GB, Chantler C, Hill RC. Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatr Nephrol 1990;4:618-22. https://doi.org/10.1007/BF00858637
- De Palo T, Giordano M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004;19:337-40. https://doi.org/10.1007/s00467-003-1364-1
- Warady BA, Sabath RJ, Smith CA, Alon U, Hellerstein S. Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 1991;5:718-23. https://doi.org/10.1007/BF00857883
- Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48. https://doi.org/10.1038/ki.1989.18
- Muller-Wiefel DE, Sinn H, Gilli G, Scharer K. Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 1977;8:481-6.
- St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005;46:650-60. https://doi.org/10.1053/j.ajkd.2005.06.018
- Warady BA, Zobrist RH, Wu J, Finan E; Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 2005;20:1320-7. https://doi.org/10.1007/s00467-005-1904-y
- Tenbrock K, Muller-Berghaus J, Michalk D, Querfeld U. Intravenous iron treatment of renal anemia in children on hemodialysis. Pediatr Nephrol 1999;13:580-2. https://doi.org/10.1007/s004670050747
- Gillespie RS, Wolf FM. Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 2004;19:662-6. https://doi.org/10.1007/s00467-004-1421-4
- Leijn E, Monnens LA, Cornelissen EA. Intravenous iron supplementation in children on hemodialysis. J Nephrol 2004;17:423-6.
- Morgan HE, Gautam M, Geary DF. Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 2001;16:779-83. https://doi.org/10.1007/s004670100645
- Van Damme-Lombaerts R, Herman J. Erythropoietin treatment in children with renal failure. Pediatr Nephrol 1999;13:148-52. https://doi.org/10.1007/s004670050584
- Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9. https://doi.org/10.1038/ki.1996.487
- Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C, Galler M. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005;68:1801-7. https://doi.org/10.1111/j.1523-1755.2005.00598.x
- Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, Ungkanont A, Bunyaratvej A Indices of iron status in continuous ambulatory peritoneal dialysis patients, Am J Kidney Dis 1999;34:29-35. https://doi.org/10.1016/S0272-6386(99)70104-6
- Coyne D. Iron indices: what do they really mean- Kidney Int Suppl 2006;69:S4-8.
- Jones CH, Richardson D, Ayers S, Newstead CG, Will EJ, Davison AM, Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Nephrol Dial Transplant 1998;13:2873-6. https://doi.org/10.1093/ndt/13.11.2873
- Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths ssociated with intravenous iron preparations, Nephrol Dial Transplant 2005;20:1443-9. https://doi.org/10.1093/ndt/gfh820
- Yorgin PD, Belson A, Sarwal M, Alexander SR. Sodium ferric gluconate therapy in renal transplant and renal failure patients. Pediatr Nephrol 2000;15:171-5. https://doi.org/10.1007/s004670000453
- Greenbaum LA, Pan CG, Caley C, Nelson T, Sheth KJ. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients. Pediatr Nephrol 2000;14:908-11. https://doi.org/10.1007/s004670000326
- Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, Dahl NV, Watkins SL. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-61. https://doi.org/10.1007/s00467-004-1457-5
- Richardson D, Bartlett C, Jolly H, Will EJ. Intravenous iron for CAPD populations: proactive or reactive strategies- Nephrol Dial Transplant 2001;16:115-9. https://doi.org/10.1093/ndt/16.1.115
- Harmeet Singh, John Reed, Sylvia Noble, Jose L. Cangiano, David B, Van Wyck. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 2006;1:475-82. https://doi.org/10.2215/CJN.01541005
- Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 1998;9:664-8.
- Anbu AT, Kemp T, O'donnell K, Smith PA, Bradbury MG. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin. Acta Paediatr 2005;94:1738-41. https://doi.org/10.1080/08035250500281921
- Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO. Iron metabolism in haemodialysis patients: A study of the management of iron therapy and overload. Q J Med 1979;48:369-91.
- Kletzmayr J, Horl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002;17(Suppl 2):25-9.
- Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-80. https://doi.org/10.1681/ASN.2005040423
- Weinberg ED. Iron withholding: A defense against infection and neoplasia. Physiol Rev 1984;64:65-102.
- Seifert A, Von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. QJ Med 1987;65:1015-24.
- Hoen B, Kessler M, Hestin D, Fondu P, Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicenter prospective survey, Nephrol Dial Transplant 1995;10:377-81.
- Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Horl WH, Fodinger M, Sunder-Plassmann G, Vychytil A. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients, Kidney Int 2005;68:2814-22. https://doi.org/10.1111/j.1523-1755.2005.00754.x
- Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005;46:283-9. https://doi.org/10.1053/j.ajkd.2005.04.032
- Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001;38:988-91. https://doi.org/10.1053/ajkd.2001.28587